|Bcl-2 (Cell-free assay)|
|In vitro (25°C)||DMSO||83 mg/mL (200.73 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
|In vivo||30% PEG400/0.5% Tween80/5% propylene glycol||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||24.18 mL||120.92 mL||241.84 mL|
|0.5 mM||4.84 mL||24.18 mL||48.37 mL|
|1 mM||2.42 mL||12.09 mL||24.18 mL|
|5 mM||0.48 mL||2.42 mL||4.84 mL|
*The above data is based on the productmolecular weight 413.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Solubility||DMSO>83mg/mL Water<1mg/mL Ethanol<1mg/mL|
|Storage||at -20°C 3 years Powder|
ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2.
Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial c…
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32μM, 0.48μM and 0.18μM.
ABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apopto…